Summit Therapeutics to Present Ivonescimab at Key December Healthcare Conferences

Summit Therapeutics Showcases Ivonescimab at Upcoming Healthcare Conferences

Summit Therapeutics Inc. is set to participate in key industry events, the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both scheduled for December 3 and 4, 2024, in Miami. At these conferences, the management team will present insights into their investigational bispecific antibody, ivonescimab, also known as SMT112 in various regions. This novel therapeutic approach integrates immunotherapy through PD-1 blockade with anti-angiogenesis via VEGF inhibition, aiming to enhance the precision of cancer treatment. The presentations will be available live on Summit’s website, emphasizing the company’s commitment to transparency and engagement with stakeholders.

Ivonescimab features a tetravalent structure that significantly boosts its binding affinity, showcasing over an 18-fold increase to PD-1 and a more than 4-fold increase to VEGF when both are present. This dual-action mechanism allows for improved targeting of tumor tissues where PD-1 and VEGF are more prevalent, leading to potential advancements in therapeutic efficacy. The antibody has a half-life of 6 to 7 days and has already seen over 1,800 patients treated in clinical trials worldwide. The development of ivonescimab represents a strategic step towards innovative cancer treatment options, particularly for non-small cell lung cancer (NSCLC), where ongoing Phase III clinical trials are currently in progress.

As part of its clinical development strategy, Summit has begun enrollment for the Phase III trials named HARMONi and HARMONi-3 in 2023, with plans to initiate HARMONi-7 in early 2025. This robust pipeline underscores Summit's dedication to advancing its investigational therapies and improving patient outcomes in oncology. The company’s focus on the unique properties of ivonescimab reflects a broader trend in the biopharmaceutical industry towards developing more effective targeted therapies that leverage the complex interactions within the tumor microenvironment.

In addition to showcasing ivonescimab, Summit Therapeutics’ participation in these conferences highlights its commitment to engaging with the healthcare community. The live presentations will provide valuable insights into the company’s research efforts and future directions, aligning with its mission to drive innovation in cancer treatment. The forthcoming discussions are anticipated to generate interest among healthcare professionals and investors alike, as the company continues its trajectory in the competitive oncology landscape.